EuroBioForum 2013 2nd Annual Conference 27-28 May 2013 - Hilton Munich City, Munich, Germany http://www.eurobioforum.eu/2013 ======================================= # REGIONAL PERSPECTIVES # EuroBioMed, France: Private-public collaborations to boost open innovation Dr Franck Molina President of EDCA, Chair of diagnosis group of Eurobiomed Director of Sysdiag ======================================= http://www.eurobioforum.eu

1. Franck Molina, Montpellier, France
Franck.molina@sysdiag.cnrs.fr
http://sysdiag.cnrs.fr
Private Public collaboration to boost open innovation

2. Diagnostic in mutation
+5-6%
+14-15%
Change of paradigm with the
convergence of diagnosis and
therapy, going to personalized
medecine and theranostic
New role of biomarker in biomedical
and therapeutic, molecular assay
development (nucleic acid,
proteines, metabolites)
explosion of POC Technologies and
of home monitoring/testing)
Integration with IT
New interfaces electronic/biology
(Biosensor)
Annualmarkerb€
Diagnostic tests represent less than 5% of hospital cost
and about 1.6 % of all health cost. Their results influence
up to 60-70% medical decision”
Source = The Lewin Group, Inc., The Value of Diagnostics Innovation, Adoption and Diffusion into Health Care,July 2005
+8%

3. Clinical
question Biomarkers
Where is performed the test
Who is taking the decision
Direct Cost
Undirect Cost
reliability
Mobility / miniaturization
Communication
Remote control
Screening
Diagnosis
Monitoring
Companion test
Medical
Device
Ethic
Security
Juridic
Coupling Biology with electronics
Biosensors

4. Translational Medicine

5. Diagnostic / Personnalized medicine
innovation is highly interdisciplinary
 scientific :
biology, biochemistry, genetic
chemistry
physic
mathematic
computing
robotic
Etc.
 medical
medecine
clinic
pharmacology
etc.
 business
Business strategy / IP
Finance
Socio-economic impact
Marketing
Regulation
Sales
Ethics
Business
motivation
Scientist
motivation
Reduce possibilities
Increase possibilities
Reduce possibilities

6.  Crossing disciplines for innovation in Diagnosis
 Combining experimental biology and complex systems modelling approaches
 70% experimentalists and 30% theoreticians
The SysDiag model
Public / private mix and interdisciplinary

7. SysDiag’s missions are :
• to understand the bases of chronic and multifactorial diseases
(neurodegenerative and cardiovascular diseases, cancer, diabetes...)
• to identify new biomarkers associated with these pathological
conditions
• to provide innovative solutions for clinicians that will contribute to
improve the health and quality of life of their patients.
Dicovery innovation Industrial Transfert R/D Production

8. Eurobiomed, Southern French
Health cluster
Medicen
Paris
CancerBioSanté
Toulouse
LyonBioPôle
Lyon
Alsace Biovalley
Starsbourg
Eurobiomed
Marseille
French health clusters
Smart-specialization in medical Diagnosis

9. Eurobiomed Mission Eurobiomed Added Value
Develop Life science potential via
dedicated and adapted working
groups: Euromediag,
Ophtabiotech…
- Develop and federate a
network of healthcare
stakeholders
- Provide development support
for companies
- Foster the implementation of
R&D collaborative projects
Eurobiomed Sharing
Strong international cooperation
network in:
- Diagnostics  access to 350
SME in EU
- Neurorescue  EU
Neuroscience community
To support
 400 companies
 4 science & technology parks
 Over 6000 academic
researchers
 3000 industrial researchers
 4 top-ranked universities

10. Eurobiomed : to create value and employment
Networking
Companies’
Growth
Transnational
project support
Market access
R&D
partnership /
platform Innovation/
funding/
regulatory/
HR
International
development
Events

11. From innovation
to patient
benefit
Build and manage
a network of In
Vitro diagnostic
experts
Contribute to the
economic
development of
these regions
Spain
Scotland
Canada
India
China
Poland
US
England
Germany
Sweden
European
diagnostic
cluster
Alliance
>350 SMEs
Wales
European Diagnostic Cluster Alliance
Brasil

12. WP1 Organization/structure/Funding (short term)
Main Resp. EuroMediag, Vice-resp: Wal-Dx
WP2 Mapping/Sharing expertise (DB) (short term)
Main Resp. Wal-Dx Vice-resp: Krakow
WP3 Access to the market/SME growth (long term)
Reshaping Diag Market/Practices…
Main Resp. OBN, Vice-resp: Nexxus, Uppsala Bio
WP4 Cooperation Model Comp/Acad/Clinic
Main Resp.ZMDB Vice-resp: BioCat
Support from:
T. PETRIN, European Cluster Policy Group
EDCA implementation

13. Market Reshaping ?
Patient Individual Behavior
Clinician
Decision
Patient
benefit
Diag / MD
Industry
Pharma
Industry
Laboratories
test
Clinician
Prescrition
treatment
Clinician
Needs
Alternative routes to consumers
New practices
New technologies
New regulatory issues
Etc.
Room for innovation
New innovative actors to come into the field
Patient centred strategiesResearch
Patient associations

14. What do we need ?
Open-innovation targeting :
- Individual or close to the patient market
New technologies (@health), niche innovation,
Mainly inspired by patient demand or new clinical practices
Interdisciplinary partnership, SMEs growth opportunities
- Specialized laboratory asssay market
Heavy technology,
Mainly inspired by clinician demand
large public/private consortia (including pharma),
To run/support international pionner projets able to induce :
market reshaping (new clinical practices)  European « Patient Leadership »
Early and dynamic interaction between innovation and Regulation

15. More than 350 reachable compagnies
Network of technological platforms
A set of international partnership events
Scientific, Clinical and Regulation expertise